RE: Fight everyone who’s concerned9 Sep 2025 13:39
So did your research miss how, this time last year, the company posted the following?
• Group revenues for H1 2024 of US$1.1m (H1 2023: US$0.1m), reflecting increased commercial traction
• Operating expenses for H1 2024 of US$4.6m (H1 2023 US$7.7m), reflecting the focus of expenditures in the
highest value areas
• Successfully raised gross proceeds of US$12.6m (£9.9m), including the participation of existing strategic partners
NUKEM Isotopes GmbH and Bracco Imaging S.p.A., and certain Directors and management of the Company,
extending cash runway until at least Q1 2026
• With the H1 2024 revenue and orders received to date, the Company is raising its revenue guidance for 2024 to
a range of $2.5m to $3.0m
Then in the annual results it said:
"We ultimately surpassed the top end of our guidance, delivering revenue of US$3.1 million for the year.
"We maintained a disciplined approach to spending, reducing cash operating expenses to US$8.5 million in 2024—down significantly from US$11.1 million in 2023. In June 2024, we completed a financing that generated gross proceeds of US$12.6 million. The Company ended the year with a cash balance of US$12.1 million."
So H2 rev for 2024 was $2m (because, for the hard of maths, FY $3.1m - H1 $1.1m = $2m). The company expects to exceed this rev rate in 2025:
"...Supported by a robust pipeline of opportunities the Company has been actively building over the past year it remains confident in achieving its previously stated revenue guidance range of US$5.0 million to US$6.0 million."
So that's between 25% and 50% higher than POLX's best two financial quarters ever. And with a $12m cushion in place even before a penny is earned. Even allowing for a (pretty bleedin' unlikely) 50% increase in cash costs and for only the bottom end of that revenue guidance to be achieved, there would still be $4.25m in the bank, which in turn would still be enough to trade through to Q3 2026, all things being equal.
So what we are saying here (aren't we?) is that *in the worst-case scenario*, the company's expectation from this time last year that its cash balance would run to Q1 2026 has in fact been extended until Q3/4 '26. And, yet, despite that positive, in the 12 months since it was reported, the share price has - literally - been cut in half.
The company has been quite clear that the bulk of rev would come in during the back end of the year, just as it did last year. I'm actually *really* looking forward to the results. From a technical perspective, it would take very little indeed for price to shrug off the downtrend line it has been anchored to since June. Look at the three-month chart: an expanding, descending wedge is extremely bullish.
I for one believe price will meet expectations very soon. But then, I have the luxury of being able to wait, since, having an average price of 1.05p on my purchases I don't have the gnawing fury of having got in at 30p. I expect that would cloud my